Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.
Carvedilol was granted FDA approval on 14 September 1995.
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- Conditions
- Heart FailureVentricular Dysfunction, Left
- Interventions
- Drug: DiureticsDrug: HF treatment according to Swedish guidelinesProcedure: Blood samplesProcedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT00391846
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
A Comparison of the Effect of Carvedilol and Metoprolol on Airways Tone in Patients With Heart Failure
- Conditions
- Heart FailureChronic Obstructive Airway Disease
- Interventions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- The Alfred
- Registration Number
- NCT00384566
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
Effects of Carvedilol on Health Outcomes in Heart Failure
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2006-09-27
- Lead Sponsor
- Denver Health and Hospital Authority
- Target Recruit Count
- 100
- Registration Number
- NCT00381030
- Locations
- 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States
Therapy With Verapamil or Carvedilol in Chronic Heart Failure
- Conditions
- Dilated Cardiomyopathy
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 100
- Registration Number
- NCT00374465
- Locations
- 🇵🇱
Silesian Centre for Heart Disease, 3rd Department of Cardiology, Zabrze, Szpitalna 2 st., Poland
The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2016-12-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 654
- Registration Number
- NCT00347360
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50000
- Registration Number
- NCT00344513
A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure
- Conditions
- Congestive Heart Failure
- Interventions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- CTI-1, LLC
- Target Recruit Count
- 318
- Registration Number
- NCT00323037
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
🇺🇸The Lindner Clinical Trial Center, Cincinnati, Ohio, United States
🇺🇸University Hospital, Cincinnati, Ohio, United States
RATe Control in Atrial Fibrillation
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Asker & Baerum Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT00313157
- Locations
- 🇳🇴
Vestre Viken Hospital Trust, Baerum Hospital, Rud, Akershus, Norway
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 514
- Registration Number
- NCT00273052
- Locations
- 🇵🇷
GSK Investigational Site, Rio Piedras, Puerto Rico
Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- Cardiovascular Clinical Studies
- Target Recruit Count
- 400
- Registration Number
- NCT00272805
- Locations
- 🇺🇸
Idaho Cardiology Associates, Boise, Idaho, United States
🇺🇸St. Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸Charlotte Heart Group Research Center, Port Charlotte, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.